Exome therapy for Autism Spectrum Disorder, PANS, Autoimmune Encephalopathy ,Neurological Lyme and Other Inflammatory Conditions in Children

I recently evaluated an autistic patient with tickborne bartonella in the office for immunoglobulin therapy (IVIG). This patient was severely impaired and combative rendering treatment regimens nearly impossible to implement. Sadly, we could not administer the immunoglobulins, a 6-8 hour IV infusion, to provide neuroinflammatory relief. This reminded me of exome therapy. We provide this in office, admittedly not often enough.

Bioactive nanoparticles formerly known as exomes are cellular sub-particles that originate from platelets, mesenchymal stem cells and tumoral cells. These sub-particles are housed in the eukaryotic compartment of a cell and can target a cells activity, modulating it. These nanoparticles contain a specific set of proteins that can merge with other cells to share cellular content. It’s easiest to view exomes as “shapeshifters” as they look to balance cellular dysfunction by turning certain functions of a cell on and off to establish homeostasis.

In clinical practice and multiple studies, exome therapy has been shown to improve neurological conditions and chronic inflammation as seen in those with Autism Spectrum Disorder, Alzheimers disease, chronic Lyme and autoimmune disorders.

nanoparticles in conjunction with stem cells work to modulate macrophages specifically and stimulate anti-inflammatory effects by inhibiting IL-17, an inflammatory T-cell, and triggering IL-10 a regulatory cell to balance and block proinflammatory TNF alpha and IL 1 beta.

Stem cells and nanoparticles used in my practice are placental based growth factor extracted post-partem from healthy, post-delivery placentas, no embryos involved!

Autism spectrum disorder (ASD) patients in my practice suffer overwhelmingly from gut issues, often referred to as “leaky gut”. This is related to elevated levels of inflammatory cytokines and immune dysfunction. Gut issues are linked to neurological inflammation which can stimulate the behavioral component in many ASD kids. By alleviating neuroinflammation we can temper many of the neurocognitive and behavioral struggles of this particular population.

stem cells and nanoparticles can be delivered intranasally and intravenously once a month for three months and prove to regulate microglial cells in the brain that contribute to neuroinflammation.

80% of patients who receive exome therapy show neurocognitive and inflammatory improvement.

Alzheimers studies show similar effects with exome therapy.

The same basic function of exome therapy can be applied to patients afflicted with autoimmune diseases like autoimmune encephalopathy and PANS, neuro-Lyme, and other tickborne illnesses by modulating microglial and macrophage activation in the brain. Exomes once injected migrate to the areas in most need making it a highly individualized treatment.

Be Well!

Somer

References

Alessio, N.; Brigida, A.L.; Peluso, G.; Antonucci, N.; Galderisi, U.; Siniscalco, D. Stem Cell-Derived Exosomes in Autism Spectrum Disorder. Int. J. Environ. Res. Public Health 2020, 17, 944. https://doi.org/10.3390/ijerph17030944

Bhasin M, Wu M, Tsirka SE. Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitis. BMC Immunol. 2007 Jul 16;8:10. doi: 10.1186/1471-2172-8-10. PMID: 17634104; PMCID: PMC1937009.